Risk of Hypoglycemia in Type 2 Diabetes
This trial is active, not recruiting.
|Condition||type 2 diabetes|
|Sponsor||University of Giessen|
|Collaborator||Merck Sharp & Dohme Corp.|
|Start date||July 2008|
|End date||September 2009|
|Trial size||12 participants|
|Trial identifier||NCT00734669, EC 84/08|
The aim of this study is to establish the risk and frequency of non-symptomatic hypoglycemia in type 2 diabetes under previous therapy with glibenclamide. Participants will be monitored via a continuous glucose monitoring system in a standardized clinical setting during day and night time, implementing meals and exercise of moderate intensity performed in the postprandial state.
Type 2 diabetic patients on glibenclamide
Number of hypoglycemic events
time frame: 3 days
Secretion of hormones increasing blood glucose, effect of exercise on hypoglycemic events, postprandial glucose excursions, heart rate and forearm blood flow at hypoglycemia
time frame: 3 days
Male or female participants at least 18 years old.
Inclusion Criteria: - Type 2 diabetes on glibenclamide with or without - Glycated hemoglobin ≤ 7.5% - Stable dosage for three weeks Exclusion Criteria: - HbA1c > 7.5% - Fasting C-peptide below normal - Concurrent infectious disease - Pregnancy - Malignant disease - Inability to give informed consent
|Official title||Risk of Hypoglycemia in Type 2 Diabetes - Effects of Glibenclamide and Exercise on Cardiovascular, Hormonal, and Metabolic Parameters|
|Description||The day-to-day change of blood glucose is associated with the frequency of vascular complications and the quality of life of diabetic patients. In this study the frequency of hypoglycemic events in combination with postprandial hyperglycemia in type 2 diabetic patients on oral insulinotropic therapy will be observed. Using more sophisticated technology than before the probability of type 2 diabetic patients on glibenclamide to experience hypoglycemic episodes will be registered. Hypoglycemia is prone to cardiovascular complications in type 2 diabetic patients due to concomitant dysregulation of blood flow. With standardized test meals followed by exercise in a clinical setting hormonal counterregulation and cardiovascular parameters associated with hypoglycemia will be identified. The acute effect of different conditions of exercise and a single dose of either glibenclamide or placebo will be followed each day during the total three-day observation period. Thus we will evaluate the frequency of and the risk factors associated with hypoglycemia and meal-related hyperglycemia in type 2 diabetic patients.|
Call for more information